Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

ImmunityBio, Inc. (IBRX)

Compare

3.0500

+0.0900

+(3.04%)

At close: 4:00:01 PM EDT

2.9499

-0.10

(-3.28%)

After hours: 6:13:38 PM EDT

ImmunityBio to Host Investor Day

CULVER CITY, Calif., March 26, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company’s business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials.

Business Wire 7 days ago

IBRX
+3.04%
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

CULVER CITY, Calif., March 13, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty services, is one of the first providers to participate in ImmunityBio’s Expanded Access Program (EAP) for recombinant Bacillus Calmette-Guérin (rBCG) to address the current shortage of TICE® BCG in the U.S.

Business Wire 20 days ago

IBRX
+3.04%
Top Growth Companies With Insider Stakes For March 2025

As of March 2025, the U.S. stock market is experiencing increased volatility, with significant corrections in major indices like the Nasdaq Composite due to ongoing trade policy uncertainties and concerns over high valuations. Amid these turbulent conditions, growth companies with high insider ownership often attract attention because their stakes suggest a strong alignment between management and shareholder interests, potentially offering resilience in challenging economic climates.

Simply Wall St. 26 days ago

AAON

CDRE

IBRX
+3.04%
US High Growth Tech Stocks to Watch in March 2025

Over the last 7 days, the United States market has dropped 3.1%, yet it remains up by 13% over the past year with earnings anticipated to grow by 14% per annum in the coming years. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation potential and adaptability to maintain momentum amidst fluctuating market conditions.

Simply Wall St. 28 days ago

IBRX
+3.04%
RYTM

DDOG
ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ImmunityBio ( NASDAQ:IBRX ) Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from FY...

Simply Wall St. 29 days ago

IBRX
+3.04%
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

CULVER CITY, Calif., March 03, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the fourth-quarter and full year ended December 31, 2024.

Business Wire 30 days ago

IBRX
+3.04%
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

CULVER CITY, Calif., February 28, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ANKTIVA® and CAR-NK (PD-L1 t-haNK) for the reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer.

Business Wire last month

IBRX
+3.04%
Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Apple (AAPL) announced the iPhone 16e, available starting February 28 Arista Networks (ANET) reported better-than-expected Q4 results and provided upbeat Q1 revenue guidance Howard Hughes (HHH) confirmed receipt of an unsolicited takeover proposal from Pershing Square Analog Devices (ADI) reported upbeat Q1 results, raised its quarterly dividend by 8%, and boosted its share repurchase aut

TipRanks last month

EA

TCEHY

TCTZF
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

CULVER CITY, Calif., February 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative source of BCG, a standard-of-care medicine in bladder cancer, to patients in the U.S.

Business Wire last month

IBRX
+3.04%
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

CULVER CITY, Calif., February 13, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application for ANKTIVA. The MHRA will now begin assessing the marketing authorization application (MAA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive

Business Wire last month

IBRX
+3.04%
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Ltd.), a global oncology company, to conduct a confirmatory randomized Phase 3 clinical trial (ResQ201A-NSCLC), combining BeiGene's tislelizumab, a PD-1 checkpoint inhibitor (CPI), and ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-pmln). The Phase 3 ResQ201A-NSCLC study (NCT06745908) aims to co

Business Wire 2 months ago

IBRX
+3.04%
Exploring High Growth Tech Stocks in the United States

The market remained flat over the last week but is up 23% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can capitalize on these favorable conditions.

Simply Wall St. 2 months ago

KNSA

IBRX
+3.04%
VRRM
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

CULVER CITY, Calif., January 27, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun assessing the marketing authorization application (MAA) for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tu

Business Wire 2 months ago

IBRX
+3.04%
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to both the European Union (EU) European Medicines Agency (EMA) and the United King

Business Wire 2 months ago

IBRX
+3.04%
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC).

Business Wire 2 months ago

IBRX
+3.04%
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

CULVER CITY, Calif., January 06, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the Centers for Medicare & Medicaid Services (CMS) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) became effective January 1, 2025. The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsiv

Business Wire 2 months ago

IBRX
+3.04%
High Growth Tech Stocks to Watch in December 2024

The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving industry landscape.

Simply Wall St. 3 months ago

IBRX
+3.04%
EXEL

MVIS
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and com

GlobeNewswire 3 months ago

IBRX
+3.04%
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

CULVER CITY, Calif., December 11, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All o

Business Wire 3 months ago

IBRX
+3.04%
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

CULVER CITY, Calif., December 10, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, ImmunityBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.

Business Wire 3 months ago

IBRX
+3.04%

Performance Overview

Return	IBRX	S&P 500 (^GSPC)
YTD	+19.14%	-3.58%
1-Year	-42.13%	+8.94%
3-Year	-47.50%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ImmunityBio, Inc. (IBRX)

ImmunityBio to Host Investor Day

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Top Growth Companies With Insider Stakes For March 2025

US High Growth Tech Stocks to Watch in March 2025

ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Exploring High Growth Tech Stocks in the United States

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

High Growth Tech Stocks to Watch in December 2024

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Performance Overview